top of page

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$358.8M

Burn Rate (Qtr)

$46.4M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

MRUS

BPIQ_Logo_RGB-01.jpg

Company Profile

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.

Recent Posts

See what the community is saying - click to see full post.

#AACR24: Hedge Funds Hold These Cancer Companies

Over 20 Smid-Cap Biopharmas Presenting at AACR 2023!

Trade Alert - ASCO Abstracts Released Today

June 2022 Big Mover™ Stocks and Movers to Watch Report

ASCO 2022 Annual Meeting (American Society of Clinical Oncology) - Clinical Trial Presentations

SABCS Presenters - Updated

bottom of page